Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 4/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596282 | 0.87 | RET (0.62) | CBLBBRAFKDRMAPK14TNNI3K | |
| SCHEMBL6016945 | 0.86 | KDR (0.42) | CBLBBRAFKDRMAPK14TNNI3K | |
| SCHEMBL3591965 | 0.83 | RAF1 (0.47) | BRAFKDRRAF1KDM1ARCOR1 | |
| SCHEMBL3593297 | 0.83 | BRAF (0.48) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL3602119 | 0.83 | KDR (0.49) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL3589751 | 0.82 | KDR (0.53) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL6017011 | 0.81 | FAAH (0.51) | BRAFKDRRAF1KDM1ARCOR1 | |
| SCHEMBL3603688 | 0.76 | KDR (0.49) | BRAFKDRRAF1KDM1ARCOR1 | |
| SCHEMBL3604416 | 0.74 | GRM5 (0.48) | RAF1 | |
| SCHEMBL3594043 | 0.74 | RAF1 (0.53) | BRAFRAF1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | CBLB 1945/4885BRAF 1/4885KDR 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.